Breaking News, Financial News

Bristol-Myers Squibb

Plavix continued to lead the way, as Abilify revenues slipped and other products showed growth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 2Q10 2Q10 Revenues: $4.8 billion (+2%) 2Q10 Earnings: $927 million (-6%) YTD Revenues: $9.6 billion (+7%) YTD Earnings: $1.7 billion (+3%) Comments: Plavix sales were $1.6 billion for 2Q10 (+6%) and $3.3 billion YTD (+11%). Abilify sales dropped 2% to $633 million in 2Q10 and were up 1% to $1.2 billion YTD. Several products showed strong growth in 2Q10, including Baraclude (+25% in 2Q10 to $223 million), Sprycel (+23% to $132 million), and Orencia (+20% to $17...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters